Successful long-term management of spasticity in people with multiple sclerosis using a software application: Results from a randomized, controlled, multicenter study.
app
multiple sclerosis
patient participation
rehabilitation
spasticity
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
20
01
2022
received:
02
12
2021
accepted:
02
02
2022
pubmed:
6
2
2022
medline:
10
5
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
Successful long-term treatment of spasticity in people with multiple sclerosis (pwMS) is challenging. We investigated the effects of multidisciplinary inpatient rehabilitation (MIR) and an individualized self-training program delivered by an app on spasticity in pwMS. First, we assessed the efficacy of 4-week MIR in ambulatory pwMS (Expanded Disability Status Scale < 7.0) with moderate to severe lower limb spasticity (defined by ≥4 points on the Numeric Rating Scale for spasticity [NRSs]) in a cohort of 115 pwMS at seven rehabilitation centers in Austria. In the case of a clinically relevant improvement in spasticity of ≥20% on the NRSs following MIR (n = 94), pwMS were randomly allocated in a 1:1 ratio to either the newly designed MS-Spasticity App or to a paper-based self-training program for 12 weeks. The primary outcome was change in NRSs (German Clinical Trials Registry DRKS00023960). MIR led to a significant reduction of 2.0 points on the NRSs (95% confidence interval [CI] = 2.5-2.0, p < 0.000). MIR was further associated with a statistically significant improvement in spasticity on the Modified Ashworth Scale, strength, and all mobility outcomes. Following MIR, self-training with the MS-Spasticity App was associated with a sustained positive effect on the NRSs, whereas paper-based self-training led to a worsening in spasticity (median NRSs difference = 1.0, 95% CI = 1.7-0.3, p = 0.009). The MS-Spasticity App was also associated with a significantly better adherence to self-training (95% vs. 72% completion rate, p < 0.001). In pwMS, MIR is able to significantly improve lower limb spasticity, strength, and mobility. Following MIR, an individually tailored antispasticity program delivered by an app leads to sustained positive long-term management.
Sections du résumé
BACKGROUND AND PURPOSE
Successful long-term treatment of spasticity in people with multiple sclerosis (pwMS) is challenging. We investigated the effects of multidisciplinary inpatient rehabilitation (MIR) and an individualized self-training program delivered by an app on spasticity in pwMS.
METHODS
First, we assessed the efficacy of 4-week MIR in ambulatory pwMS (Expanded Disability Status Scale < 7.0) with moderate to severe lower limb spasticity (defined by ≥4 points on the Numeric Rating Scale for spasticity [NRSs]) in a cohort of 115 pwMS at seven rehabilitation centers in Austria. In the case of a clinically relevant improvement in spasticity of ≥20% on the NRSs following MIR (n = 94), pwMS were randomly allocated in a 1:1 ratio to either the newly designed MS-Spasticity App or to a paper-based self-training program for 12 weeks. The primary outcome was change in NRSs (German Clinical Trials Registry DRKS00023960).
RESULTS
MIR led to a significant reduction of 2.0 points on the NRSs (95% confidence interval [CI] = 2.5-2.0, p < 0.000). MIR was further associated with a statistically significant improvement in spasticity on the Modified Ashworth Scale, strength, and all mobility outcomes. Following MIR, self-training with the MS-Spasticity App was associated with a sustained positive effect on the NRSs, whereas paper-based self-training led to a worsening in spasticity (median NRSs difference = 1.0, 95% CI = 1.7-0.3, p = 0.009). The MS-Spasticity App was also associated with a significantly better adherence to self-training (95% vs. 72% completion rate, p < 0.001).
CONCLUSIONS
In pwMS, MIR is able to significantly improve lower limb spasticity, strength, and mobility. Following MIR, an individually tailored antispasticity program delivered by an app leads to sustained positive long-term management.
Banques de données
DRKS
['DRKS00023960']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1697-1707Informations de copyright
© 2022 European Academy of Neurology.
Références
Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589-595.
Fox RJ, Bacon TE, Chamot E, et al. Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry. Neurodegener Dis Manag. 2015;5:3-10.
Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis-clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129:154-162.
Lance JW. Pathophysiology of spasticity and clinical experience with Baclofen. In Lance JW, Feldman RG, Young RR, Koella WP, (Eds.). Spasticity: Disordered Motor Control. Year Book; 1980;185-204.
Hugos CL, Cameron MH. Assessment and measurement of spasticity in MS: state of the evidence. Curr Neurol Neurosci Rep. 2019;19:79.
Biering-Sørensen F, Nielsen JB, Klinge K. Spasticity-assessment: a review. Spinal Cord. 2006;44:708-722.
Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the multiple sclerosis spasticity Scale (MSSS-88). Brain. 2006;129:224-234.
Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther. 2008;30:974-985.
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122-1131.
Markovà J, Essner U, Akmaz B, et al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 2019;129:119-128.
Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler. 2016;22:1386-1396.
Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev. 2013;28:CD009974.
Harvey LA, Katalinic OM, Herbert RD, Moseley AM, Lannin NA, Schurr K. Stretch for the treatment and prevention of contractures. Cochrane Database Syst Rev. 2017;9:CD007455.
Haselkorn JK, Balsdon Richer C, Fry Welch D, et al. Overview of spasticity management in multiple sclerosis. evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med. 2005;28:167-199.
Asano M, Duquette P, Andersen R, Lapierre Y, Mayo NE. Exercise barriers and preferences among women and men with multiple sclerosis. Disabil Rehabil. 2013;35:353-361.
Ehling R, Edlinger M, Hermann K, et al. Successful long-term management of spasticity in patients with multiple sclerosis using a software application (APP): a pilot study. Mult Scler Relat Disord. 2017;17:15-21.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
Umbrella Organisation of the Social Insurance Agency. Online Referencing. https://rehakompass.goeg.at/#/start. Accessed 1 December 2021.
Vickers AJ. How to randomize. J Soc Integr Oncol. 2006;4:194-198.
Bohannon RW, Smith MB. Interrater reliability of a modified ashworth scale of muscle spasticity. Phys Ther. 1987;7:206-207.
Demeurisse G, Demol O, Robaye E. Motor evaluation in vascular hemiplegia. Eur Neurol. 1980;19:382-389.
Dite W, Temple VA. A clinical test of stepping and change of direction to identify multiple falling older adults. Arch Phys Med Rehabil. 2002;83:1566-1571.
Timed-25-Foot-Walk. Online referencing. https://www.nationalmssociety. org/For-Professionals/Researchers/Resources-for-MS-Researchers/Research-Tools/Clinical-Study-Measures/Timed-25-Foot-Walk-(T25-FW). Accessed 1 December 2021.
Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982;284:1607-1608.
Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512-515.
Flachenecker P, Müller G, König H, et al. Fatigue" in multiple sclerosis. Development and validation of the "Würzburger Fatigue Inventory for MS. Nervenarzt. 2006;77(165-166):168-170, 172-174.
Petermann F. Hospital anxiety and depression scale, deutsche version (HADS-D). Zeitschrift für Psychiatr Psychol und Psychother. 2011;59:251-253.
Morfeld M, Kirchberger I, Bullinger M. SF-36 Fragebogen zum Gesundheitszustand. German Version of the Short Form-36 Health Survey. 2006. www.hogrefe.de
Hugos CL, Bourdette D, Chen Y, Chen Z, Cameron M. A group-delivered self-management program reduces spasticity in people with multiple sclerosis: a randomized, controlled pilot trial. Mult Scler J Exp Transl Clin. 2017;23(3):2055217317699993.
Boesen F, Nørgaard M, Trénel P, et al. Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - the danish MS hospitals rehabilitation study. Mult Scler. 2018;24:340-349. 10.1177/1352458517735188
Hvid LG, Gaemelke T, Dalgas U, et al. Personalised inpatient multidisciplinary rehabilitation elicits clinically relevant improvements in physical function in patients with multiple sclerosis - the danish MS hospitals rehabilitation study. Mult Scler J Exp Transl Clin. 2021;7:2055217321989384.
Baert I, Freeman J, Smedal T, et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study. Neurorehabil Neural Repair. 2014;28:621-631.
Baert I, Smedal T, Kalron A, et al. Responsiveness and meaningful improvement of mobility measures following MS rehabilitation. Neurology. 2018;91(20):e1880-e1892.
Kalron A, Feys P, Dalgas U, et al. Searching for the "active ingredients" in physical rehabilitation programs across Europe, necessary to improve mobility in people with multiple sclerosis: a multicenter study. Neurorehabil Neural Repair. 2019;33:260-270.
Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Techno Assess. 2003;7:1-111.
Řasová K, Freeman J, Cattaneo D, et al. Content and delivery of physical therapy in multiple sclerosis across europe: a survey. Int J Environ Res Public Health. 2020;31:886.
Baz-Valle E, Schoenfeld BJ, Torres-Unda J, Santos-Concejero J, Balsalobre-Fernández C. The effects of exercise variation in muscle thickness, maximal strength and motivation in resistance trained men. PLoS One. 2019;14:e0226989.